Olaparib and talazoparib currently are the only PARPi approved for patients with hormone receptor-positive/HER2-negative advanced breast cancer and a BRCA1 or BRCA2 mutation detected by germline sequencing. Here, NR4A1 is linked to breast carcinoma.